British pharmaceutical giant AstraZeneca has conceded that its Covid vaccine, Covishield, can lead to a rare side effect, as reported by The Telegraph (UK). The admission comes amidst a class action lawsuit in the UK alleging severe injuries and deaths caused by the vaccine.
Covishield, developed by AstraZeneca and Oxford University and manufactured by the Serum Institute of India, has been widely administered globally.
AstraZeneca faces legal action from victims in 51 cases in the UK High Court, seeking damages up to 100 million pounds. The first complainant, Jamie Scott, claims to have suffered permanent brain injury due to a blood clot after receiving the vaccine in April 2021.
While AstraZeneca contests the claims, it admitted in court documents in February that Covishield can cause Thrombosis with Thrombocytopenia Syndrome (TTS), a condition characterized by blood clots and low platelet count.
The admission contradicts the company’s previous stance in 2023, when it denied TTS being caused by the vaccine at a generic level.
AstraZeneca’s acknowledgment may lead to compensations for victims and their families, though the company maintains its vaccine is not defective and its efficacy is not overstated.
For more updates follow our Whatsapp 
and Telegram Channel 
